By Maria Armental 

Gilead Sciences Inc. swung to a loss in the June quarter following the Forty Seven Inc. acquisition and reflecting higher costs as it ramps up production of Covid-19 drug remdesivir.

Remdesivir, was authorized for emergency use in the U.S. in May, and Gilead began charging for the drug in July.

On Thursday, Gilead said expenses more than doubled in the quarter to $8.13 billion, outpacing revenue gains, largely due to higher clinical trial and manufacturing ramp-up expenses related to remdesivir.

Overall, Gilead reported a loss of $3.34 billion, or $2.66 a share, compared with a year earlier profit of $1.88 billion, or $1.47 a share. On an adjusted basis, profit fell to $1.11.

Revenue, meanwhile, fell 10% to $5.14 billion.

Analysts surveyed by FactSet expected a loss of 69 cents a share, or adjusted profit of $1.44, on $5.29 billion in revenue.

The drugmaker had warned that about $200 million in sales had moved into the March quarter, primarily in the U.S., as customers stocked up on prescription medicines during the pandemic.

Sales of HIV drug Biktarvy, which more than doubled in the March quarter, rose 44% to $1.6 billion in the second quarter.

"Gilead's first half performance demonstrates the strength and durability of our core HIV business, even as we navigated the expected impact of the COVID-19 pandemic," Chief Executive Daniel O'Day said in a statement, adding that Gilead was seeing early signs of recovery.


Write to Maria Armental at


(END) Dow Jones Newswires

July 30, 2020 16:31 ET (20:31 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more Gilead Sciences Charts.